PD-L1:B7-1[Biotinylated] Inhibitor Screening Assay Kit

The PD-L1:B7-1[Biotinylated] Inhibitor Screening Assay Kit is an ELISA-based assay designed to measure the binding between PD-L1 (programmed death-ligand 1) and B7-1 (also known as CD80) protein for screening and profiling applications. This kit comes with enough purified PD-L1 (amino acids 19-239) and biotinylated B7-1 (amino acids 35-242), streptavidin-HRP, assay buffer, and detection reagent for 100 enzyme reactions.Figure 1. PD-L1:B7-1[Biotinylated] Inhibitor ScreeningAssay Kit schematic..A 96-well plate is coated with PD-L1 protein. After coating and blocking, biotinylated B7-1 is added in an optimized assay buffer. Next, unbound biotinylated B7-1 is washed away, and the plate is incubated with streptavidin-HRP. After a final wash, ELISA ECL substrate is added to produce chemiluminescence that can be measured using a chemiluminescence reader. The chemiluminescence signal is proportional to the efficacy of B7-1 binding to PD-L1.Need us to run inhibitor screens or profile your compounds against PD-L1:B7-1 [Biotinylated]? Check out ourImmunotherapy Biochemical Screening Services.

Product Specifications

Background

PD-1 (Programmed Death Protein 1, CD279) is a transmembrane protein expressed on the surface of immune cells that binds to PD-L1 or PD-L2, inducing apoptosis of T cells and inhibiting immune responses. Cancer cells often overexpress PD-L1 or PD-L2, allowing them to suppress T cell activation, evade the host immune response, and proliferate. Thus, disrupting the PD-1 co-inhibitory pathways may be an effective approach to developing anti-cancer therapies, as well as other immune diseases like multiple sclerosis, arthritis, lupus, and type I diabetes. PD-L1 can also bind to B7-1, also known as CD80. That interaction can reduce the binding of PD-L1 to PD-1 in T cells, and can increase the GvHD (graft versus host disease), and blocking its interaction can result in increased tumor immune response, making it attractive in cancer therapy.

UniProt

PD-L1: Q9NZQ7; B7-1: P33681

Applications

Study and screen compounds that inhibit the binding of PD-L1 to B7-1 for drug discovery in high throughput screening (HTS) applications.

Format

Catalog #ComponentAmountStorage71104PD-L1, Fc fusion*25 µg-80°C71114B7-1 (CD80), Fc fusion, Biotin-labeled*15 µg-80°C79742Streptavidin-HRP10 µl+4°C793113x Immuno Buffer 150 ml-20°C79728Blocking Buffer 250 ml+4°C79670ELISA ECL substrate A (transparent bottle) 6 mlRoom Temp.ELISA ECL substrate B (brown bottle) 6 mlRoom Temp.79699White 96-well microplate1+4°C*The concentration of the protein is lot-specific and will be indicated on the tube.